January 20, 2016
German Biofrontera leaving London Stock Exchange
Biofrontera, the biopharmaceutical company focusing on sun-induced skin cancer, has decided to cancel the admission of its ordinary shares to trading…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Biofrontera
November 19, 2015
Biofrontera concludes clinical phase III of BCC study. Approval of Ameluz expected in 2016
Biofrontera has concluded the clinical phase 3 of BCC study as the last patient in the ongoing phase has had its final clinical visit.
November 11, 2015
Biofrontera’s business not affected by ongoing approval processes
Biofrontera has announced that there have been no new operational developments or matters which have arisen in relation to the ongoing approval processes or other operational aspects of the Company.
September 22, 2015
Biofrontera: Ameluz and BF-RhodoLED a great team in photodynamic field therapy
Biofrontera, the biopharmaceutical company focusing on sun-induced skin cancer, has announced that preliminary long-term results of the Phase III trial for…
You must be logged in to post a comment.